Caladrius Biosciences (CLBS) Getting Favorable Media Coverage, Report Shows
News articles about Caladrius Biosciences (NASDAQ:CLBS) have been trending positive this week, according to Accern. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Caladrius Biosciences earned a daily sentiment score of 0.37 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near term.
Caladrius Biosciences (CLBS) remained flat at $4.00 during midday trading on Tuesday. The stock had a trading volume of 632 shares. The company’s 50-day moving average price is $4.69 and its 200-day moving average price is $4.51. Caladrius Biosciences has a 12-month low of $2.65 and a 12-month high of $7.79.
Caladrius Biosciences (NASDAQ:CLBS) last issued its quarterly earnings results on Thursday, May 18th. The biotechnology company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.40. The business had revenue of $7.92 million for the quarter, compared to analysts’ expectations of $9.50 million. Caladrius Biosciences had a negative return on equity of 678.79% and a negative net margin of 84.10%. On average, equities research analysts forecast that Caladrius Biosciences will post ($3.95) EPS for the current fiscal year.
CLBS has been the subject of a number of research analyst reports. Zacks Investment Research raised Caladrius Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, May 22nd. HC Wainwright set a $7.00 price target on Caladrius Biosciences and gave the company a “buy” rating in a report on Friday, May 19th. Finally, ValuEngine upgraded Caladrius Biosciences from a “strong sell” rating to a “sell” rating in a report on Saturday, June 10th.
WARNING: “Caladrius Biosciences (CLBS) Getting Favorable Media Coverage, Report Shows” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/07/18/caladrius-biosciences-clbs-receives-coverage-optimism-rating-of-0-37-updated.html.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Stock Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related stocks with our FREE daily email newsletter.